Despite the significant improvement in survival with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs), most patients with EGFR‐mutant non‐small cell lung cancer (NSCLC) develop EGFR‐TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.